Sugi Predict

Sugi Predict / Compounds / SCHEMBL599210

SCHEMBL599210

SCHEMBL599210

COc1ccc(C(=O)/C=C/C(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ F3 P13726 2/20 0.66
▸ MAPT P10636 7/20 0.65
▸ ALDH1A1 P00352 5/20 0.65
▸ MAOB P27338 5/20 0.65
▸ KMT2A Q03164 3/20 0.65
▸ MEN1 O00255 2/20 0.65
▸ HSPD1 P10809 1/20 0.65
▸ TNFRSF1A P19438 1/20 0.65
▸ HSPE1 P61604 1/20 0.65
▸ CYP1B1 Q16678 1/20 0.65
▸ HPGD P15428 2/20 0.64
▸ THRB P10828 2/20 0.63
▸ LMNA P02545 2/20 0.63
▸ HTT P42858 1/20 0.63
▸ NPSR1 Q6W5P4 1/20 0.63
▸ XDH P47989 2/20 0.63
▸ BCHE P06276 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ NFKB1 P19838 1/20 0.60
▸ NFKB2 Q00653 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL599211 1.00 F3 (0.66) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL11020483 0.95 F3 (0.60) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL11020485 0.95 F3 (0.60) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL10938343 0.93 ALDH1A1 (0.77) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL10938338 0.93 ALDH1A1 (0.77) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL7000261 0.92 F3 (0.75) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL7000262 0.92 F3 (0.75) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL3687472 0.85 F3 (0.66) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL3687467 0.85 F3 (0.66) F3MAPTALDH1A1MAOBKMT2A
SCHEMBL25191040 0.84 F3 (0.87) F3MAPTALDH1A1MAOBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 304 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4661890-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS Purdue Research Foundation (US) 2025-12-17 — — EP claimed
WO-2024167565-A1 PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS PURDUE RESEARCH FOUNDATION (US) 2024-08-15 — — WO claimed
US-10072043-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2018-09-11 — — US claimed
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES Indiana University Research and Technology Corpora tion (US) 2016-06-23 — — US claimed
US-9217012-B2 Inhibitors of protein tyrosine phosphatases INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) 2015-12-22 — — US claimed
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATI (US) 2012-04-12 — — US claimed
WO-2010118241-A2 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION (US) 2010-10-14 — — WO claimed
US-7732625-B2 Colorant compounds XEROX CORPORATION (US) 2010-06-08 — — US claimed
US-7311767-B2 Forming a salt of a liquid phase change ink carrier of stearyl stearamide, an amine substituted Xanthene, acridine, anthracene or thioxanthene chromogen, and a metal salt capable of forming a compound with two chromogens XEROX CORPORATION (US) 2007-12-25 — — US claimed
US-7033424-B2 Phase change inks XEROX CORPORATION (US) 2006-04-25 — — US claimed
US-20060021546-A1 Processes for preparing phase change inks XEROX CORPORATION 2006-02-02 — — US claimed
US-20060020141-A1 Metallized dye XEROX CORPORATION 2006-01-26 — — US claimed
US-20060016369-A1 PHASE CHANGE INKS XEROX CORPORATION 2006-01-26 — — US claimed
US-6946025-B2 Process for preparing tetra-amide compounds XEROX CORPORATION (US) 2005-09-20 — — US claimed
US-20050090690-A1 Process for preparing tetra-amide compounds XEROX CORPORATION 2005-04-28 — — US claimed
EP-1441721-A2 USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES MERCK PATENT GmbH (DE) 2004-08-04 — — EP claimed
WO-2003039539-A2 USE OF ENDOTHELIN RECEPTOR ANTAGONISTS IN THE TREATMENT OF TUMOUR DISEASES MERCK PATENT GMBH (DE) 2003-05-15 — — WO claimed
EP-0309262-B1 Novel salicylates, their salts, pharmaceutical compositions containing them and process for preparing same RICHTER GEDEON VEGYESZET (HU) 1994-02-02 — — EP claimed
CN-119019389-B 7-Azaindole compound and synthetic method and application thereof SICHUAN UNIVERSITY (CN) 2026-05-26 — — CN disclosed
US-4211786-A Mercaptoacyldihydropyrazole carboxylic acid derivatives E. R. SQUIBB & SONS, INC. (US) 1980-07-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10072043-B2 Inhibitors of protein tyrosine phosphatases PTPRCAP, PTPRF, PTPRS F3 3326/4885MAPT 2153/4885ALDH1A1 3087/4885
US-20160176922-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS F3 3326/4885MAPT 2153/4885ALDH1A1 3087/4885
US-20060020141-A1 Metallized dye CDYL, CDY1; CDY1B, CDYL2 F3 1004/4885MAPT 4074/4885ALDH1A1 1569/4885
US-20050090690-A1 Process for preparing tetra-amide compounds TAF9, TAF5, TAF1 F3 956/4885MAPT 539/4885ALDH1A1 1723/4885
US-20120088720-A1 INHIBITORS OF PROTEIN TYROSINE PHOSPHATASES PTPRCAP, PTPRF, PTPRS F3 3326/4885MAPT 2153/4885ALDH1A1 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.